Independent. No paid rankings. Our evidence grades are never for sale. Where a cosmetic or skincare product passes our review, we may link to it with a disclosed affiliate link. Reviewed weekly Editorial policy Newsletter

Home›Explore peptides›GLP-1 reimbursement in France

Is Wegovy or Mounjaro covered by insurance in France?

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 15 September 2026Funding No vendor payment

Since 15 June 2026, France has been the first European Union country to add semaglutide (Wegovy) and tirzepatide (Mounjaro) to its standard reimbursement list for adult obesity, not just diabetes. The headline rate is 65%, most qualifying patients actually get 100%, and a restriction most coverage announcements skip past is that your GP can renew that prescription but usually can't be the one who first writes it.

On this page

  1. The short version
  2. Who actually qualifies
  3. 65% on paper, 100% in practice for most
  4. Why your GP usually can't write the first prescription
  5. How this compares elsewhere in the EU
  6. What this doesn't change

In brief

Should you care? Yes, if you're in France and have seen headlines that these drugs are "now reimbursed" — the real picture is narrower and more procedural than that framing suggests, and where you can actually fill the prescription depends on rules most coverage doesn't mention.

The short version

  • What changed: two ministerial orders (23 May 2026, corrected and reissued 10 June 2026) added Wegovy and Mounjaro to France's reimbursable-medicines list for severe adult obesity, effective 15 June 2026 — a first for any EU country.
  • Who qualifies: a BMI of 40+, or 35+ with an obesity-related comorbidity, after a documented failed attempt at nutritional care — not simply wanting to lose weight.
  • The catch on access: only certain obesity specialists and hospital-linked structures can write the first reimbursable prescription; a general practitioner can renew it afterward, but not start it.

The short version

On 15 June 2026, France became the first European Union country to put semaglutide (Wegovy) and tirzepatide (Mounjaro) on its ordinary reimbursement list for adult obesity itself, rather than only for the type 2 diabetes indication these same molecules already had (as Ozempic and, less widely, generic tirzepatide). Health Minister Stéphanie Rist announced the move on 28 May 2026; two ministerial orders dated 23 May 2026 (Journal officiel, 28 May) set the reimbursement in motion, and were then replaced — same effective date, same underlying eligibility rules — by a further pair of orders dated 10 June 2026 that widened and clarified exactly which specialists count for the all-important first prescription. The headline reimbursement rate is 65%, but the health minister has said publicly that most people who actually qualify end up covered at 100%, for a structural reason explained in §3.

Who actually qualifies

This isn't "ask your doctor for a slimming jab and Sécu picks up part of the tab." The eligibility bar, set by the Haute Autorité de Santé's Commission de la Transparence (a first favorable opinion for Wegovy in December 2024, followed by a further opinion in December 2025 — after the health ministry made an urgent referral asking which sub-populations should be prioritized first) requires:

  • a body mass index of 40 kg/m² or higher, regardless of other conditions; or
  • a BMI of 35 kg/m² or higher with at least one obesity-related comorbidity (commonly type 2 diabetes, hypertension, or similar); and, either way,
  • a documented attempt at nutritional and lifestyle care that has already failed to produce adequate weight loss.

The reimbursement applies specifically to Wegovy FlexTouch (semaglutide) and Mounjaro KwikPen (tirzepatide) at their obesity dosing and branding. It does not touch Ozempic — the lower-dose, diabetes-labelled semaglutide brand — which has been reimbursed on its own, separate terms for years and is unaffected by this change either way.

65% on paper, 100% in practice for most

The base Assurance Maladie reimbursement rate set for both drugs is 65%, applied to a price negotiated between the government's pricing committee (CEPS) and each manufacturer — Novo Nordisk for Wegovy, Eli Lilly for Mounjaro. CEPS doesn't publish the exact net price it agrees to; French press coverage of the announcement converged on a figure in the neighborhood of €300 a month as the reference price reimbursement is calculated against. But Minister Rist has said openly that because most patients who clear the BMI-40, or BMI-35-plus-comorbidity, bar already carry a qualifying long-term condition (a French "ALD" such as diabetes or cardiovascular disease) that itself carries 100% coverage, the practical reimbursement rate for the bulk of eligible patients is 100%, not 65%. The minister put the projected cost to public finances at roughly €100 million a year once prescribing ramps up, against an estimated eligible population of around a million people.

Before this change, both drugs were available in France only as a cash purchase at around that same list price (Wegovy had briefly been supplied free to about 3,000 patients under a temporary early-access program that Novo Nordisk ran through the end of 2025). Reimbursement doesn't change the shelf price — it changes who pays what share of it, and only for patients who meet the criteria above.

Why your GP usually can't write the first prescription

The rule that has drawn the most pushback isn't the BMI threshold — it's who's allowed to start you on a reimbursable prescription at all. Under both the original and the corrected order, the first reimbursable prescription is reserved for doctors working in a designated obesity-care structure: a Centre Spécialisé de l'Obésité (CSO), a university hospital (CHU), a specialist "SMR" rehabilitation unit in gastroenterology/endocrinology/nutrition, or an endocrinologist working in connection with a CSO. A general practitioner can renew that prescription once a specialist has started it, but cannot initiate it — and the prescriber has to complete an official justification form, through Assurance Maladie's own online portal, that's handed to the pharmacist alongside the prescription.

MG France, the general practitioners' union, publicly objected within days of the announcement, arguing that routing every new patient through a comparatively small pool of specialist structures makes the reimbursed drugs "practically inaccessible" in areas without easy access to one. The government's stated reasoning is the opposite concern — guarding against inappropriate use and unchecked cost growth by keeping the initial prescribing decision inside specialist obesity care. Both things can be true at once: the rule is real, and so is the access bottleneck it creates.

The second round of orders, issued just before the 15 June start date, didn't retreat from that restriction — it widened and clarified which specific specialists and structures qualify, while leaving the BMI/comorbidity criteria and the 65% headline rate unchanged.

How this compares elsewhere in the EU

France's move is genuinely a first, not a formality — most of the EU's other large economies still don't reimburse either drug for weight loss at all, and Sweden makes the point in its starkest form of any country here: its own benefits agency rejected even a narrower, sickest-patients-only application twice in 2026, not because the drug doesn't work but because it couldn't guarantee the restriction would hold in practice. Ireland is one entry on this table that doesn't fit a clean yes/no — it already reimburses one older GLP-1-class drug for weight management on a narrow protocol, while Wegovy and Mounjaro both sit mid-assessment with no decision yet. Italy is a different kind of exception again: it passed the world's first dedicated national obesity law over a year ago, formally declaring obesity a chronic disease — but that legal recognition still hasn't turned into a euro of GLP-1 reimbursement for it. Portugal, the newest addition to this table, sits closest to France's approach of anyone else here without actually joining it: a government-commissioned cost study, a promised decree, and — already live, short of that decree — a widening of coverage for the diabetes-labeled version of the same drug.

How eleven European countries treat GLP-1 obesity drugs for reimbursement, as of September 2026
CountryReimbursed for obesity?Basis
FranceYes, since 15 Jun 2026BMI ≥40, or ≥35 with a comorbidity, after failed nutritional care; 65% base rate, 100% for most via existing ALD status.
GermanyNoThe G-BA has formally listed Wegovy in its Medicines Directive as a "lifestyle drug" excluded under §34(1) SGB V; a Mainz social court upheld a statutory fund's refusal to pay in June 2025. The diabetes indication is unaffected.
NetherlandsNot yetZorginstituut Nederland gave a negative recommendation in 2024 and, as of a November 2025 update, is still re-assessing new manufacturer data in phases, starting with the highest-severity patients — no addition to the basic package has been confirmed as of this review.
DenmarkNoThe Danish health ministry has estimated that reimbursing the roughly 900,000 Danes with a BMI of 30 or higher could cost on the order of $3.5–4 billion a year — a figure widely cited as the reason a national scheme hasn't moved forward.
BelgiumNo, since 3 Jun 2026INAMI's own reimbursement commission (CRM) issued a negative opinion on Wegovy, citing insufficient quality-of-life benefit, weight regain on discontinuation, and a projected cost of several billion euros a year if scaled to every eligible patient. Full page here, including a separate February 2026 crackdown on fraudulent diabetes-indication claims.
PolandNo — neither indication is currently reimbursedAOTMiT's president has issued negative recommendations against reimbursing tirzepatide (Mounjaro) for BOTH indications proposed to date: No. 151/2025 (October 2025) against the type 2 diabetes indication, and No. 87/2026 (29 June 2026) against a proposed new obesity drug program (BMI 35+ with a complication). Neither recommendation disputed the underlying trial data — both cited uncertainty over how durable the effect is, weighed against the cost to Poland's National Health Fund (NFZ), estimated at roughly 130 million złoty in year one rising to about 424 million złoty in year two for the obesity indication. Neither recommendation is the final word — Poland's Health Minister makes the binding call on each, and hadn't published a decision on either as of this review — but as things stand today, tirzepatide is not reimbursed in Poland for any indication. A separate Wegovy (semaglutide) obesity application was still awaiting both a Transparency Council position and a President's recommendation.
SwedenNo — rejected twice in 2026TLV (the Dental and Pharmaceutical Benefits Agency) rejected Novo Nordisk's Wegovy application on 19 February 2026, covering both adults (BMI ≥35 with three obesity-related conditions, or BMI ≥40 with two) and adolescents aged 12–18 with a BMI of 35 or higher — citing, for the adult group, an inability to guarantee the drug would reach only the intended patients (widely reported as a "subsidy drift" risk) rather than any dispute over efficacy, and pointing to the roughly 675 million kronor Swedes already spent on Wegovy privately in 2025 as evidence prescribing wouldn't stay within the requested group; for adolescents, TLV separately rated obesity's severity in that age group as only moderate rather than high, pushing the cost per quality-adjusted life year above what it considers reasonable. Novo Nordisk appealed the full February decision — both patient groups — to the Stockholm Administrative Court in March 2026; after refiling a dedicated, adolescents-only application in June 2026 (rejected again on 2 July 2026, on the separate, procedural ground that TLV couldn't rule on a pediatric case while the adult one remained pending), it withdrew the pediatric portion of its court appeal, leaving only the adult rejection still before the court. Mounjaro has never had a reimbursement decision either way — Eli Lilly filed its own obesity-indication application in August 2026 — yet had already become Sweden's best-selling medicine by November 2025, entirely as a private purchase, and stayed in that position through 2026.
IrelandPartial — one older drug only, since 2023; Wegovy and Mounjaro both still pendingIreland is the odd one out on this table: it already reimburses liraglutide (Saxenda) for weight management, but only under a narrow Managed Access Protocol running since 1 January 2023 — BMI 35+ with prediabetes and high cardiovascular risk, and treatment stops if a patient hasn't lost at least 5% of body weight after 12 weeks on the full 3mg dose (4,139 patients were approved under it in 2023 alone). Wegovy is a separate, still-open question: Novo Nordisk applied for HSE reimbursement on 19 March 2025 (reference HSE100033), a rapid review recommended a full health-technology assessment that May, Novo's full submission didn't arrive until 23 February 2026, and as of this review the National Centre for Pharmacoeconomics (NCPE) has sent back a preliminary review and is still awaiting Novo's response — no decision either way, over a year after the original application. Mounjaro has moved further: the NCPE completed its full assessment on 3 December 2025 and said it could be reimbursed if its cost-effectiveness improves — in plain terms, at a lower price — and a February 2026 parliamentary answer confirmed the HSE's own pricing unit had met with Eli Lilly and was awaiting a revised proposal. By June 2026, the NCPE's own Michael Barry told Irish press that Lilly had already offered a significant price reduction and that Mounjaro would likely now be judged cost-effective — but as of this review, no final reimbursement decision has actually been published either way.
ItalyNo — but a world-first law says it should be, eventuallyItaly became the first country anywhere with a dedicated national obesity law: Law No. 149/2025 (passed by the Chamber of Deputies with cross-party support, approved unanimously in the Senate, published in the Gazzetta Ufficiale on 9 October 2025 and in force from 24 October 2025) formally classifies obesity as a chronic, progressive and relapsing disease, and creates the legal basis for eventually folding its diagnosis and treatment into Italy's Essential Levels of Care (LEA) — the list of services the national health service (SSN) must provide, free or cost-shared. "Eventually" is the operative word: the law doesn't itself add any drug to the LEA list, that requires separate follow-on decrees and Regional-level implementation, and none of that has reimbursed a GLP-1 drug for obesity as of this review, nearly a year after the law took effect. Wegovy and Mounjaro both remain Class C for the obesity indication — 100% patient-paid, roughly €300–400 and €300–500 a month respectively — while Mounjaro's separate type 2 diabetes indication has been fully reimbursed since 23 February 2025 under AIFA's prescribing note (Nota 100). Health Minister Orazio Schillaci signed a decree setting up the law's National Observatory for the Study of Obesity on 19 June 2026 (published 28 July 2026), alongside funding that rises from €700,000 in 2025 to €800,000 in 2026 and €1.2 million a year from 2027 — real money, but for research and coordination infrastructure, not drug reimbursement. Days before this review, the Italian Society for Bariatric Surgery (SICOB), through its president Maurizio De Luca, publicly urged the government to issue the law's still-outstanding implementing decrees, ahead of its September 2026 national congress — a sign the "law exists, but the cure doesn't yet" gap is a live domestic complaint, not just an outside observation.
PortugalNo — but a dedicated regime is being drafted, and coverage for the diabetes brand already widened in Feb 2026Despacho n.º 13066/2025 (6 November 2025, Cabinet of the Secretary of State for Health) created Portugal's National Program for Prevention and Management of Obesity and gave Infarmed 30 days to model the cost of reimbursing obesity medicines. Infarmed's resulting technical study, published 23 December 2025, put the two-year cost of covering the roughly 170,405 to 180,880 patients who meet the Directorate-General of Health's Integrated Care Pathway for People with Obesity (PCIPO) eligibility criteria at somewhere between €194.8 million (at a 15% co-payment rate) and €954.4 million (at 90%) — and recommended that any exceptional reimbursement regime carry explicit eligibility criteria given the cost. Infarmed's president, Rui Santos Ivo, confirmed in March 2026 that the agency was still drafting the decree that would actually create that regime; as of this review, no such decree has been published, and Wegovy and Mounjaro both remain fully patient-paid for the obesity indication — Portuguese patients spent roughly €55 million on GLP-1 drugs in the first quarter of 2026 alone, per Infarmed's own sales data. Separately, and already in force: since 2 February 2026, the SNS widened its existing reimbursement of Ozempic (semaglutide, the diabetes-labeled brand) to adults with type 2 diabetes who also have a BMI of 30 kg/m² or higher or a high cardiovascular risk — removing a narrower eligibility gate rather than creating a new obesity indication — still at Portugal's standard reimbursement rate for this drug class (90%, or 95% for pensioners). That change reaches many more diabetic patients, but it isn't a weight-loss reimbursement and doesn't touch Wegovy, the higher, obesity-labeled dose.
SpainNo — rejected three times in 2025; Mounjaro excluded tooWegovy has been sold in Spanish pharmacies as a private, cash-only purchase since May 2024, at list prices that have run from roughly €180 (starter doses) to €292 (the 2.4mg maintenance dose) a month — it has never been part of the Sistema Nacional de Salud's (SNS) reimbursement list for obesity. Novo Nordisk brought the obesity indication before the Comisión Interministerial de Precios de los Medicamentos (CIPM), the government body that approves reimbursement in Spain, three separate times in 2025 (July, September and October), and the CIPM rejected all three, citing Article 92(d) of the consolidated medicines law (Real Decreto Legislativo 1/2015): budgetary impact and the rationalization of public pharmaceutical spending, not any dispute over the drug's clinical evidence. At the same December 2025 CIPM round that confirmed those refusals, the commission also declined to widen Ozempic's own existing diabetes-indication reimbursement to reach a broader, weight-related eligibility group — the same kind of move Portugal made two months later — and separately withheld reimbursement from Mounjaro (tirzepatide) altogether; as of this review Eli Lilly's drug has no SNS-funded indication in Spain at all, diabetes included. The one place Spain's health ministry has moved is price on drugs it already funds: a CIPM decision effective 1 February 2026 cut Ozempic's reimbursed price from €82.09 to €75.52 a pen and Rybelsus's from €85.50 to €79.13 a box of 30 tablets, later extended to two further Ozempic presentations later that month — cost containment on an existing diabetes benefit, not a new one. Novo Nordisk separately cut Wegovy's own private list price from 1 March 2026 (14% on the 1.7mg dose, 17.6% on the 2.4mg dose, to €200.19 and €223.64 a month) as part of a wider European access initiative — a voluntary manufacturer move with no bearing on SNS reimbursement, which for the obesity indication remains exactly where it was in 2024: zero.

What this doesn't change

This is a reimbursement decision, not a new approval — semaglutide and tirzepatide were already authorized medicines in France before 15 June 2026, the same "approved isn't the same as covered" gap this site's Canadian insurance page describes. A doctor outside the specialist pathway above can still write you a prescription; it simply won't carry the reimbursement. Falling under the BMI-40 (or 35-plus-comorbidity) line, even with a doctor's support, doesn't currently qualify either. And nothing here touches the diabetes-indication pathway for semaglutide or tirzepatide, which has run on its own separate reimbursement terms for years. See Semaglutide and Tirzepatide for the underlying drugs' evidence and approval history, including how the UK's NHS and Australia's PBS ration access on their own, different terms.

What you can do next

References

  1. Légifrance, arrêté du 23 mai 2026 modifiant la liste des spécialités pharmaceutiques remboursables aux assurés sociaux (Journal officiel n°0123, 28 May 2026), and arrêté du 10 juin 2026 modifying and replacing it (Journal officiel n°0136, 12 June 2026) — legifrance.gouv.fr. Both texts are the primary legal basis for the reimbursement described on this page; search Légifrance for the current in-force version rather than relying on this summary, since a repealed-and-replaced order can be harder to locate by date alone.
  2. Ameli.fr (Assurance Maladie), "Obésité : de nouveaux médicaments peuvent être pris en charge dans des conditions encadrées"; Haute Autorité de Santé, Commission de la Transparence opinion on Wegovy (semaglutide), 4 December 2024, and Avis n°2025.0075/AC/SEM, 18 December 2025, on priority sub-populations among patients eligible for Wegovy and Mounjaro — has-sante.fr.
  3. Reuters wire reporting on Health Minister Stéphanie Rist's 28 May 2026 announcement, corroborated independently by Euronews, The Local France, RTÉ News, The Connexion, and U.S. News & World Report, on the 15 June 2026 effective date, the ~€300/month negotiated price, the 65% base reimbursement rate, and France's status as the first EU country to take this step; Vidal.fr and Caducee.net (French medical trade press) on the prescriber-restriction rules and MG France's public objection.
  4. Gemeinsamer Bundesausschuss (G-BA), press release confirming Wegovy's listing as an excluded "lifestyle" medicine under §34(1) SGB V — g-ba.de; independently corroborated reporting on the Sozialgericht Mainz ruling (June 2025) upholding a statutory insurer's refusal to cover it.
  5. Zorginstituut Nederland, "Zorginstituut: obesitasmedicijnen eerst beschikbaar voor mensen met hoogste ziektelast," 6 November 2025 — zorginstituutnederland.nl; independently corroborated by NOS and KNMP reporting on the phased re-assessment and the institute's negative 2024 recommendation.
  6. Reporting on the Danish Health Ministry's cost estimate (roughly $3.5–4 billion a year to reimburse GLP-1 drugs for the country's BMI-30-plus population), cited across multiple English-language outlets as the stated reason Denmark has not adopted a reimbursement scheme.
  7. Frank Vandenbroucke's 3 June 2026 ministerial statement and independently corroborating Belgian press (La Libre, RTBF, Le Spécialiste) on the CRM's negative opinion regarding Wegovy — see this site's dedicated Belgium page for the full sourcing.
  8. Agencja Oceny Technologii Medycznych i Taryfikacji (AOTMiT), Rekomendacja nr 87/2026 Prezesa Agencji z dnia 29 czerwca 2026 r., on Mounjaro KwikPen (tirzepatyd) in the proposed drug program "Leczenie choroby otyłościowej (ICD-10: E66)" — bip.aotm.gov.pl. Independently corroborated by Polish pharmacy trade press — Portal opieka.farm ("AOTMiT nie rekomenduje refundacji tirzepatydu w chorobie otyłościowej"), mgr.farm ("AOTMiT przeciw refundacji Mounjaro w otyłości"), Cowzdrowiu.pl ("Co z refundacją Mounjaro? Jest decyzja AOTMiT"), and farmacja.pl — on the recommendation number, date, BMI-35-plus-complications eligibility proposed, the ~130M/~424M PLN year-one/year-two NFZ budget-impact figures, and the reasoning (durability of effect and cost, not efficacy). AOTMiT Recommendation No. 151/2025 (22 October 2025) is a SEPARATE, also-negative recommendation against reimbursing tirzepatide for its type 2 diabetes indication — corroborated across the same sources plus glp1.com.pl, balticmed.pl, and mojacukrzyca.org, all consistent that tirzepatide currently has no reimbursed indication in Poland at all, for either diabetes or obesity, pending the Health Minister's decision on both.
  9. Tandvårds- och läkemedelsförmånsverket (TLV), "TLV subventionerar inte läkemedlet Wegovy för behandling av obesitas" (press release) and "TLV beslutar att Wegovy inte ska ingå i högkostnadsskyddet" (underlying decision), both published 23 February 2026 (decision dated 19 February 2026) — tlv.se. Independently corroborated by Library of Congress, Global Legal Monitor, "Sweden: Government Agency Refuses to Subsidize Weight Loss Drug Wegovy, Citing High Costs," 5 March 2026 (loc.gov), and by Swedish trade press — Läkemedelsvärlden ("Wegovy mot obesitas får ingen subvention"), Svensk Farmaci, and Läkartidningen ("Wegovy får nobben — ska inte ingå i läkemedelsförmånen") — on the same decision date, the adult (BMI ≥35 plus three comorbidities, or BMI ≥40 plus two) and adolescent (12–18) eligibility criteria Novo Nordisk applied for, TLV's own estimate that roughly 1.6 million people fall within Wegovy's potential scope of use, and the SEK 675 million (roughly $74.7 million) Swedes spent on unsubsidized Wegovy in 2025 that TLV cited as evidence of the risk.
  10. Novo Nordisk Scandinavia, press releases "Novo Nordisk överklagar TLV-beslut" (17 March 2026) and "Novo Nordisk utvecklar talan till förvaltningsrätten" (30 April 2026), on its appeal of TLV's full 19 February decision — covering both the adult and adolescent patient groups — to the Förvaltningsrätten (Administrative Court) in Stockholm; and "Novo Nordisk ansöker om subvention för barn och ungdomar med obesitas" (5 June 2026), confirming the company withdrew the adolescent portion of that same court appeal once it filed a separate, dedicated pediatric application, leaving only the adult rejection under appeal — mynewsdesk.com.
  11. Läkartidningen, "Ny ansökan om Wegovy till barn avvisas"; Life Science Sweden, "Juridisk knut stoppar ny prövning av Wegovy för barn"; Svensk Farmaci, "Novo Nordisk ansöker på nytt om subvention för Wegovy för barn" (5 June 2026) and "'Mycket förvånade och besvikna över detta drastiska beslut från TLV'" (7 July 2026) — independently corroborating TLV's 2 July 2026 rejection of the adolescents-only re-application on the stated ground that the pediatric case couldn't be decided while the adult appeal remained before the Stockholm court, TLV's own "moderate severity" reasoning for the youth group, and Novo Nordisk's reaction.
  12. Svensk Farmaci, "Mounjaro är nu Sveriges mest sålda läkemedel" (4 December 2025), reporting November 2025 sales of roughly 157.3 million kronor that made Mounjaro Sweden's single best-selling medicine, unreimbursed, ahead of Eliquis; Läkemedelsvärlden, "Mounjaro har nu sålt för mer än en miljard kronor" (on passing SEK 1 billion in sales by May 2026) and "Lilly ansöker om subvention för Mounjaro — efter Wegovys nej"; Svensk Farmaci, "Eli Lilly ansöker om att Mounjaro ska subventioneras vid obesitas" (4 August 2026) — on Mounjaro remaining Sweden's best-selling medicine throughout 2026 while still unreimbursed, and Eli Lilly's own August 2026 subsidy application for the obesity indication, undecided as of this review.
  13. HSE Medicines Management Programme, Managed Access Protocol for liraglutide (Saxenda) for weight management in adults, effective 1 January 2023 — healthservice.hse.ie/hse.ie; ISPOR/Value in Health Europe 2024 poster and Value in Health journal publication on baseline characteristics of the 4,139 patients approved for reimbursement under the protocol in 2023, and a further ScienceDirect retrospective observational study on the same protocol's outcomes.
  14. National Centre for Pharmacoeconomics (NCPE), Ireland, "Plain English Summary" and "Technical Summary," Tirzepatide (Mounjaro), HTA ID 24024, completed December 2025 — ncpe.ie, recommending reimbursement contingent on improved cost-effectiveness; HSE response to Dáil Éireann Parliamentary Question 10654-26 (Deputy Ken O'Flynn), February 2026 — about.hse.ie, on the HSE Corporate Pharmaceutical Unit's meeting with Eli Lilly and the status of the pricing proposal as of that date; TheJournal.ie, 23 June 2026, quoting NCPE clinical director Michael Barry on Eli Lilly's subsequent price reduction offer and the likelihood Mounjaro would now be judged cost-effective.
  15. Irish Examiner, "Novo Nordisk requests HSE to cover Wegovy on medical card," and "Up to 80,000 people in Ireland may qualify for State-funded weight-loss injections" — independently corroborating Novo Nordisk's 19 March 2025 HSE reimbursement application (reference HSE100033) for Wegovy, the 14 May 2025 rapid-review recommendation for a full assessment, the 23 February 2026 full submission date, and the assessment's "awaiting response from applicant" status as of this review; Irish Times, "Weight loss drug Wegovy to cost around €220 a month as supplies go on market in Ireland" (25 March 2025), on Wegovy's Irish list price ahead of any reimbursement decision.
  16. Gazzetta Ufficiale della Repubblica Italiana, Legge 3 ottobre 2025, n. 149, "Disposizioni per la prevenzione e la cura dell'obesità," Serie Generale n. 235 (9 October 2025), in force from 24 October 2025 — gazzettaufficiale.it/eli/id/2025/10/09/25G00158/SG (primary legal text; Article 3's €700,000/€800,000/€1.2 million funding schedule and Article 4's Observatory independently corroborated by Bollettino ADAPT's and Diritto.it's own legal analyses of the same law). ANSA, "Lotta alla obesità, la Camera approva la proposta di legge," 7 May 2025, and PharmaStar/QuiFinanza/SIO (Società Italiana dell'Obesità) reporting on Roberto Pella's role as first signatory and president of the parliamentary intergroup on obesity, the bill's Chamber approval (155 votes in favour) and unanimous Senate passage, and Italy's status as the first country with dedicated obesity legislation — independently corroborated by EASO ("Italy Approves the First Law Recognizing Obesity as a Chronic Disease") and the peer-reviewed account in Obesity Facts (Karger/PMC, "Italy's Landmark Obesity Law: The Long Road from Science to Policy").
  17. Ministero della Salute, decreto ministeriale of 19 June 2026 establishing the composition of the Osservatorio per lo Studio dell'Obesità (OSO) under Law 149/2025, published in the Gazzetta Ufficiale on 28 July 2026; Sanità33 and Cronache di Scienza reporting Health Minister Orazio Schillaci's own comments on the decree and the law's 2026–2027 implementation roadmap. CanaleUno, Radio Studio90 Italia and Ragionieri e Previdenza (syndicated wire reporting, September 2026) quoting SICOB (Società Italiana di Chirurgia dell'Obesità) president Maurizio De Luca's public appeal for the law's outstanding implementing decrees ahead of SICOB's 17–19 September 2026 national congress in Pisa.
  18. SISMED and GLP1-Italia.it consumer-facing pricing guides, and Medicalmente.it's summary of AIFA Nota 100 (in effect from 23 February 2025, reimbursing tirzepatide/Mounjaro at Class A for type 2 diabetes) — independently cross-checked against Il Post's 2 September 2026 reporting ("In Italia spendiamo un sacco di soldi per i farmaci come Ozempic") and AIFA's own 2026 GLP-1 prescriber guide (aifa.gov.it), confirming both drugs remain Class C (fully patient-paid) for the obesity indication as of this review, at the roughly €300–400 (Wegovy) and €300–500 (Mounjaro) monthly price ranges cited above. Il Sole 24 Ore, "Obesità: la Francia rimborsa le nuove terapie ai pazienti, l'Italia apre il dibattito," on France's 15 June 2026 reimbursement reigniting Italian domestic debate.
  19. Diário da República, Despacho n.º 13066/2025, 6 November 2025 (Gabinete da Secretária de Estado da Saúde) — diariodarepublica.pt/dr/detalhe/despacho/13066-2025-944666727 — the primary legal text creating Portugal's National Program for Prevention and Management of Obesity and instructing Infarmed to produce a costing study within 30 days. Infarmed, "Estudo de Análise de impacto da comparticipação de medicamentos para a obesidade," published 23 December 2025 — infarmed.pt — the primary costing study itself, independently corroborated on the same €194.8m–€954.4m two-year range and 170,405–180,880 eligible-patient estimate by Público, Diário de Notícias, Observador, Rádio Renascença, and Correio da Manhã, all dated 23–24 December 2025.
  20. Observador, "Infarmed a trabalhar no regime especial de comparticipação de medicamentos para obesidade," 4 March 2026, quoting Infarmed president Rui Santos Ivo confirming the obesity-reimbursement decree was still being drafted, with no publication date yet set. Público, "Ozempic comparticipado pelo SNS vai chegar a mais diabéticos: o que muda?," 3 February 2026, on the SNS's widened Ozempic (semaglutide) reimbursement to type 2 diabetes patients with a BMI ≥30 kg/m² or high cardiovascular risk, at the existing 90%/95%-for-pensioners rate — independently corroborated by RTP, ECO, JN, HealthNews.pt, and consumer body DECO Proteste, all reporting the same eligibility criteria, rate, and 2 February 2026 effective date. The Portugal News, "Portugal spending €613,000 a day on weight-loss drugs," 18 May 2026, citing Infarmed's own first-quarter-2026 sales data (roughly €55.2 million spent, over 2,300 GLP-1 packages sold daily) for the still-unreimbursed obesity indication.
  21. Comisión Interministerial de Precios de los Medicamentos (CIPM), Spain's Ministry of Health — sanidad.gob.es — the primary government body whose agreements are the legal basis for every decision on this row; its published rejections of Novo Nordisk's Wegovy (semaglutide) obesity-indication application, citing Article 92(d) of Real Decreto Legislativo 1/2015, are independently corroborated by El Economista ("Sanidad retrasará la financiación de la terapia contra la obesidad de Novo Nordisk hasta 2025," September 2024, on the application first being deferred) and El Español ("El Gobierno niega la financiación pública a Ozempic para perder peso por su 'impacto presupuestario,'" 7 November 2025), both reporting the same three 2025 rejection dates (July, September, October) and budgetary reasoning. Redacción Médica, "Mounjaro, fuera de la financiación del SNS; Ozempic no amplía indicaciones," 2 December 2025, on the same CIPM round's parallel refusal to expand Ozempic's diabetes-indication eligibility or add Mounjaro to the SNS benefit. Redacción Médica, "España baja el precio a Ozempic y Rybelsus y frena la entrada de Mounjaro," 5 February 2026, and "El SNS suma 2 presentaciones de Ozempic a los fármacos con rebaja de precio," 24 February 2026, on the CIPM's price cuts for Ozempic (€82.09 to €75.52 per pen) and Rybelsus (€85.50 to €79.13 per box), independently corroborated by El Español, 9 March 2026. Redacción Médica, "Wegovy, fármaco para perder peso, reduce su precio en España hasta un 17%," 6 March 2026, independently corroborated by Consalud and AIMFA/El Farmacéutico coverage of the same 1 March 2026 Novo Nordisk price cut, on the 14%/17.6% reductions to Wegovy's 1.7mg/2.4mg doses (to €200.19/€223.64 a month). El Economista, "Wegovy 'pincha' en su primer mes de venta en las farmacias españolas," June 2024, on Wegovy's May 2024 Spanish launch as a private, unreimbursed purchase.